Equities

Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc

Actions
  • Price (EUR)39.40
  • Today's Change0.20 / 0.51%
  • Shares traded--
  • 1 Year change+42.75%
  • Beta--
Data delayed at least 15 minutes, as of Nov 14 2024 15:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments638592552
Total Receivables, Net0.870.992.77
Total Inventory------
Prepaid expenses6.017.234.48
Other current assets, total------
Total current assets645600559
Property, plant & equipment, net191713
Goodwill, net------
Intangibles, net------
Long term investments293129--
Note receivable - long term------
Other long term assets------
Total assets965754572
LIABILITIES
Accounts payable8.608.493.82
Accrued expenses181410
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total----0
Total current liabilities272314
Total long term debt000
Total debt000
Deferred income tax------
Minority interest------
Other liabilities, total9.609.957.65
Total liabilities373322
SHAREHOLDERS EQUITY
Common stock1,4361,065783
Additional paid-in capital157142117
Retained earnings (accumulated deficit)(665)(483)(357)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.08)(3)(0.99)
Total equity928721550
Total liabilities & shareholders' equity965754572
Total common shares outstanding756352
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.